Jonathan I. Lieber - 20 Sep 2021 Form 4 Insider Report for APPLIED GENETIC TECHNOLOGIES CORP

Role
Chief Financial Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
20 Sep 2021
Net transactions value
$0
Form type
4
Filing time
21 Sep 2021, 21:25:56 UTC
Next filing
21 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGTC Stock Option (right to buy) Award $0 +202,000 $0.000000 202,000 20 Sep 2021 Common Stock 202,000 $3.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable for 25% of the underlying shares on the first anniversary of the grant date, and thereafter becomes exercisable for the remaining underlying shares in equal monthly installments over three years, resulting in the option being exercisable for 100% of the underlying shares on the fourth anniversary of the grant date.